First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data

Hiroki Ishihara, Kenji Omae, Yuki Nemoto, Ryo Ishiyama, Hidekazu Tachibana, Koichi Nishimura, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi